How We WorkOrder NowSupport Privacy

Hot Biotech Stocks in the News – GILD, CLSN, CELG, ARNA

on 04/02/2013

Houston, TX – February 4 , 2013 — (Net PR News) –, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit


Gilead Sciences, Inc. (NASDAQ:GILD) revealed that, on Monday, February 4, at 4:05 p.m. Eastern Time, it will release its financial results for the fourth quarter and fiscal year 2012. The company’s management will present a conference call at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2012’s financial results and provide a financial guidance for 2013 and general business update.

Gilead Sciences, Inc.percentage change increased +2.81% to close at $40.56 with the total traded volume of 13.03 million shares, as compared to average volume of 8.60 million shares.

Is GILD A Solid Investment At These Levels? Find Out Exactly Where GILD Is Headed With This TREND ANALYSIS REPORT

GILD’s total market capitalization is $61.46 billion, along with 1.52 billion shares outstanding. Its beta value stands at 0.46 points and its earning per share remained $1.60. Company’s lowest price during last trade was $39.94 while its highest price remained $41.14 for the day.

Celsion Corporation (NASDAQ:CLSN) reported a plunge of -12.58%, after opening at the price of $1.42. Its closing price for the day was $1.32.

Celsion Company’s earning per share is $-0.76 while its beta value stands at 1.32 times. The Company’s current market capitalization stands at $46.22 million along with 35.01 million shares. CLSN’s total trading volume for the day was 17.59 million shares, versus its average volume of 4.34 million shares.

Get A Free Report And Detailed Analysis On CLSN CLICK HERE To Read

If we look at the previous 5 day’s performance of the stock, it remained decreasing with the drop of -82.9% and, in its last one month’s trade it plunged -83.8%.

Celgene Corporation (NASDAQ:CELG) declared that it fourth quarter 2012 net product sales climbed 14 percent and remained $1,416 million. Its fourth quarter 2012 adjusted net income was recorded at $572 million, an upsurge of 21 percent as compared to the fourth quarter 2011 net income of $473 million.

Celgene Corporation percentage change increased 2.51% to close at $101.44 with the total traded volume of 5.19 million shares, as compared to average volume of 4.15 million shares.

How Should Investors React To CELG Now? Find Out In This TREND ANALYSIS REPORT

CELG’s shares were trading within the range of $99.19-$102.29, while its opening price was $99.94. Its market capitalization is $42.91 billion and EPS was $3.30. If we look at its previous three months trade, it gained 2.26%, while in the last 5 day’s it remained up 1.68%.

Another Biotechcompany showing positive moment during the previous trade, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported the increase of 1.54% and closed at $8.58 with the total traded volume of 5.81 million shares. The stock’s opening price was $8.66.

The 52-week price range of the stock remained $1.70 – $13.50, while during last trade its minimum price was $8.35 and it gained its highest price of $8.67.

The company has a total of 217.29 million outstanding shares and its total market capitalization is $1.86 billion. The Company’s last 5 days shows a downtrend -1.49%.

 How Should Investors Trade ARNA Now? Don’t Trade ARNA Until You Read This TREND ANALYSIS REPORT


Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Source: anotherwinningtrade Posted Mon, February 04, 2013 14:21 - Permalink